Cellipont Bioservices and Xiogenix Announce Strategic Partnership to Enhance Client Access to Advanced Filling Systems | PR Newswire [Video]

, /PRNewswire/ — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in biopharmaceutical technology, are pleased to announce a strategic partnership. This collaboration enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and finish system, significantly enhancing the precision and efficiency of their cell therapy product filling processes.

…committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing.

The Xiogenix Ares™ X20 is a cutting-edge fill-and-finish system designed to revolutionize cell and gene therapy production. It offers precise temperature control, automated formulation, and high-throughput capabilities, efficiently processing multiple containers in under five minutes. By minimizing residual air and waste, it ensures high-quality and consistent formulations. The Ares™ X20’s scalability and automation enhance the precision, safety, and efficiency of therapy production, representing a significant advancement in the field and potentially accelerating the time to market …